Navigation Links
Isotechnika Announces Interim Three Month Data from Phase 2b Kidney,Transplant Trial

EDMONTON, May 07, 2007 /PRNewswire-FirstCall/ - Isotechnika Inc. today announced the audited three month results, reviewed by the Data Monitoring Committee, of the first third of the patients treated in its Phase 2b de novo kidney transplant trial for the Company's lead immunosuppressive drug, ISA247.

This interim analysis is based upon the assessment of the first 116 patients enrolled. There have been 28 patients treated with the low dose (0.4 mg/kg twice daily) resulting in 11% incidence of acute rejection; 25 patients treated with the mid dose (0.6 mg/kg twice daily) resulting in 8% incidence of acute rejection; and 29 patients treated with the high dose (0.8 mg/kg twice daily) resulting in 3% incidence of acute rejection, as compared to 34 patients treated with tacrolimus, resulting in 9% incidence of acute rejection. All rejection episodes were appropriately treated. No transplanted kidneys have been lost. When all three of the ISA247 dosing groups are combined, there is a 7% rate of acute rejection in the ISA247 groups compared to a 9% rate of acute rejection in the tacrolimus group, which is being dosed optimally.

As part of the trial, kidney function is being measured on an ongoing basis by Glomerular Filtration Rate (GFR). Based on the data generated to date, very good kidney function has been observed in all of the ISA247 dosing groups. Within the first month post-transplant, kidney function showed improvement across all ISA247 dosing groups similar to that observed in the tacrolimus group. Fewer incidences of hypomagnesemia, neurological side effects, and new onset diabetes mellitus have been observed with all ISA247 dosing groups as compared to tacrolimus. There have been no clinically significant differences noted in blood pressure, lipids (cholesterol and triglycerides) or other laboratory parameters examined to date. Additionally, the strong pharmacokinetic/pharmacodynamic correlati
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Isotechnikas Lead Drug, ISA247, To Be Highlighted at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
2. Isotechnikas independent data monitoring committee conducts review of phase 2b kidney transplant trial
3. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study
Post Your Comments:
(Date:1/23/2015)... , Jan. 23, 2015  Northwest Biotherapeutics, Inc. (NASDAQ: ... immune therapies for operable and inoperable solid tumor cancers, announced ... the 7 th Annual Phacilitate Immunotherapy Forum in ... at Phacilitate will take place on January 26 at 10:30 ...
(Date:1/23/2015)... and DUBLIN , Jan. 23, ... agreement with KRS Global Biotechnology, Inc. for the compounding, packaging ... compounded for shipment in the United States ... approved Outsourcing Facility capable of compounding naltrexone tablets in various ...
(Date:1/23/2015)... Fla. , Jan. 23, 2015  HyGreen, Inc., a ... agreement and partnership with RCA Medical, a subsidiary of ... . Each year, hundreds of millions ... care-associated infections as organisms are transmitted from patient to ...
Breaking Medicine Technology:NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 2NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 3Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 2Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 3Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 4HyGreen Partners with RCA Medical in Johannesburg, South Africa 2
... 13, 2011 Life Spine, a medical device company ... surgical treatment of spine disorders, today announced that the ... offerings and technologies at the 6th Annual Spine Technology ... 12th, 2011, in Napa, California. "Life Spine ...
... MedClean Technologies, Inc. (OTC Bulletin Board: ... the treatment and disposal of medical waste and the ... it has formed a co-marketing agreement with Covidien, a ... relationship, Covidien,s national sales force for SharpSafety products will ...
Cached Medicine Technology:MedClean Technologies Forms Co-Promotion Relationship With Covidien, Leading Global Healthcare Products Manufacturer 2MedClean Technologies Forms Co-Promotion Relationship With Covidien, Leading Global Healthcare Products Manufacturer 3
(Date:1/22/2015)... The Incredible Bulk is a revolutionary method put ... muscle by up to 30lbs in less than 12 weeks ... Stan Stevenson, prompting an investigative review. , “Our Incredible ... diet formula that allows the body to pack on a ...
(Date:1/22/2015)... Blue Cross and Blue Shield of Minnesota (Blue ... means to “Live Fearless.” , The “Faces of ... stories about how they or someone they know has faced ... in the moment. By telling these types of stories through ...
(Date:1/22/2015)... 22, 2015 The federal court overseeing thousands ... District Court, Southern District of West Virginia has upheld a ... proceeding’s first bellwether trial. In an Order dated January 21st, ... after finding that C.R. Bard had not proven a miscarriage ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 A new ... of experience and person-centeredness in the long-term care environment ... action across the continuum. The paper, “The Power of ... engages perspectives and practices of the patient, resident and ...
(Date:1/22/2015)... Autocarinsurancebest.com has released a new blog post explaining ... policy . , Auto insurance quotes help many drivers ... longer necessary to call an agent or visit an agency ... a single website: http://autocarinsurancebest.com/ . , Every business who ...
Breaking Medicine News(10 mins):Health News:The Incredible Bulk: Review Examining Ben Pakulski’s Brand New Bulking Muscle Building Diet Program Released 2Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Commercial Auto Insurance Provides Several Important Features! 2
... -- Stretching before taking warm-up swings may hurt your ... passive, static stretching routine before taking practice swings results ... consistent ball contact," according to Jeffrey C. Gergely, of ... He compared two different warm-up routines in a group ...
... Admissions for alcohol abuse treatment have remained the same in ... the United States, while treatment rates for illegal drugs are ... a new report. The report, issued by the ... these findings: The overall rate of substance ...
... team of Johns Hopkins Children,s Center researchers has discovered ... regulates inflammation and cell death in emphysema and may ... findings, published online in the December issue of The ... new treatments to prevent lung damage caused by infections ...
... (HealthDay News) -- A disturbing new study finds that ... anesthesia to surgical patients, and those germs contribute to ... to think that the surgical drapes protect the patient ... and on our bodies. Nope! These studies provide evidence ...
... civilian personnel is counterproductive to NATO,s strategy for ... Stene after six months in the country. ... tasks, and present ourselves more clearly," she says. ... coordination in conflicts at the University of Stavanger, ...
... , Researchers at Washington University School of Medicine in St. ... contribute substantially to dangerous forms of the parasite Toxoplasma ... closer to new ways to beat Toxoplasma and ... Cell Host & Microbe , scientists show that the ROP18 ...
Cached Medicine News:Health News:Stretching Before Warm-Up Swings May Harm Golf Game 2Health News:Drug Abuse Treatment Rates on the Rise: U.S. Report 2Health News:Protein involved in cystic fibrosis also plays role in emphysema, chronic lung disease 2Health News:Protein involved in cystic fibrosis also plays role in emphysema, chronic lung disease 3Health News:Anesthesiologists Spreading Germs During Surgery: Study 2Health News:The too many faces of war -- why the war in Afghanistan is so complex 2Health News:The too many faces of war -- why the war in Afghanistan is so complex 3Health News:The too many faces of war -- why the war in Afghanistan is so complex 4Health News:Protein helps parasite survive in host cells 2
... Acid-labile subunit (ALS) is a GH dependent ... a 578 amino acid peptide with a predicted ... serum are mostly confined to a ~150 KDa ... molecule of IGF-I or IGF-II, and this unique ...
... The Medtronic SelectSecure Lead System (Model ... lead. Its unique, lumenless design allows for ... F) without sacrificing insulation thickness. The SelectSecure ... allow positioning of the lead in select ...
... glucuronide (3alpha-diol G) is the glucuronide ... of dihydrotestosterone (DHT) [1,2]. 3alpha-diol G ... 75% of the bioactivity of testosterone ... product of intracellular reduction of DHT, ...
... are polypeptide hormones which belong to ... The TGF- superfamily is a large ... control many aspects of development, reproductive ... members incude TGF-s, bone morphogenetic proteins, ...
Medicine Products: